Philips and Imricor launch iMR lab solution
Analysis based on 10 articles · First reported Aug 27, 2026 · Last updated Aug 27, 2026
The launch strengthens Philips' position in image-guided therapy and expands its MRI portfolio into interventional cardiology, potentially boosting demand for its 1.5T systems. For Imricor, the commercial availability of its iMR products with a major OEM partner could accelerate adoption and revenue growth, positively impacting its stock.
On August 27, 2026, Philips and Inspire Medical Systems announced the launch of a new Interventional MR (iMR) lab solution for Philips 1.5T MRI systems. The solution combines Philips' high-performance 1.5T MRI platform with Imricor's portfolio of MR-compatible systems and consumables, enabling MR-guided cardiac interventions without compromising on field strength. The first commercially available configuration includes Philips' Cardiac MR Suite with SmartHeart AI-powered planning and Imricor's NorthStar iMR mapping system, Advantage-MR EP Recorder/Stimulator, and Vision-MR electrophysiology catheters. The solution is built on Philips' BlueSeal helium-free MRI technology and is commercially available immediately in CE-marked markets and, in some configurations, the U.S. It will be showcased at ESC Congress 2026 in Munich. This launch marks a milestone in the companies' long-standing collaboration to bring MR-guided cardiac intervention into routine clinical practice, expanding the role of cardiac MRI from diagnosis into treatment.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard